Atopic Dermatitis
Latest News
Free teledermatology clinic helps underserved patients initiate AD care
The program "is meant to be a stepping point for initiating care ... to set someone up for success for recurrent telehealth visits in the future...
Latest News
When treating AD in children, experts consider adherence, other aspects of treatment
One way to avoid moving to the most expensive drugs quickly is simply verifying that patients were compliant with the drugs that were used first,...
Latest News
Ocular complications of dermatologic treatments: Advice from a pediatric ophthalmologist
There are several potential mechanisms by which biologics targeting IL-13 might increase risk of ocular complications, one of which is the role...
Feature
Camp Discovery: A place for children to be comfortable in their own skin
Chronic skin conditions carry a heavy psychological burden, but a special 1-week camp for youth 8-16 founded 30 years ago aims to lift that weight...
Latest News
JAK inhibitors efficacious for atopic dermatitis in Asian patients, study finds
The Singapore study is one of the few that have examined the safety and efficacy of JAK inhibitors for treatment of AD in a non-White population...
Latest News
New guidelines for MTX use in pediatric inflammatory skin disease unveiled
One of the recommendations states that liver biopsy is not indicated for routine monitoring of pediatric patients taking low-dose MTX.
Military Dermatology
Understanding Medical Standards for Entrance Into Military Service and Disqualifying Dermatologic Conditions
The military is a desirable career field for many young adults; however, the Department of Defense (DoD) requires its members to maintain a level...
Case Reports
Dupilumab-Associated Sweet Syndrome
Prescribers of dupilumab should be aware that Sweet syndrome is a potential adverse reaction.
Latest News
Advising patients on AD treatment options: Expert pearls
Dupilumab dosing and dupilumab-associated facial redness and ocular disease, self-image issues, topical regimen adherence, and the quantification...
Latest News
Abrocitinib remains effective at 96 weeks, in older as well as younger adults
The analysis stratified patients by age – 18-50 and over 50 years – and found that the sustained improvement with the JAK-1 selective inhibitor as...
Latest News
Dupilumab outcomes stable at end of open label atopic dermatitis study
Other recent research on the biologic has shown that it improves lesional skin barrier function and rapidly reduces the abundance of ...